中国北京 2022-2023 年延迟季节甲型流感相关门诊病人和急诊科就诊流感样病例的流感疫苗有效性。

IF 5.2 3区医学 Q1 IMMUNOLOGY

Vaccines Pub Date : 2024-09-30 DOI:10.3390/vaccines12101124

Li Zhang, Guilan Lu, Chunna Ma, Jiaojiao Zhang, Jia Li, Wei Duan, Jiaxin Ma, Weixian Shi, Yingying Wang, Ying Sun, Daitao Zhang, Quanyi Wang, Da Huo

{"title":"中国北京 2022-2023 年延迟季节甲型流感相关门诊病人和急诊科就诊流感样病例的流感疫苗有效性。","authors":"Li Zhang, Guilan Lu, Chunna Ma, Jiaojiao Zhang, Jia Li, Wei Duan, Jiaxin Ma, Weixian Shi, Yingying Wang, Ying Sun, Daitao Zhang, Quanyi Wang, Da Huo","doi":"10.3390/vaccines12101124","DOIUrl":null,"url":null,"abstract":"Background: During the 2022-2023 influenza season, the influenza activities in most regions of China were postponed, including Beijing. The unusually delayed influenza epidemic posed a challenge to the effectiveness of the influenza vaccine.Methods: Using the test-negative design, we evaluated influenza vaccine effectiveness (VE) during the 2022-2023 influenza season against influenza A-associated outpatient and emergency-department-attended influenza-like illness (ILI) in Beijing, China, from 9 January to 30 April 2023.Results: The analysis included 8301 medically attended ILI patients, of which 1342 (46.2%) had influenza A(H1N1)pdm09, 1554 (53.4%) had influenza A(H3N2), and 11 (0.4%) had co-infection of the two viruses. VE against influenza A-associated ILI patients was 23.2% (95% CI: -6.5% to 44.6%) overall, and 23.1%, 9.9%, and 33.8% among children aged 6 months to 17 years, adults aged 18-59 years, and adults aged ≥60 years, respectively. VE against influenza A(H1N1)pdm09 and against influenza A(H3N2) were 36.2% (95% CI: -1.9% to 60.1%) and 9.5% (95% CI: -34.1% to 39.0%), respectively. VE of the group with vaccination intervals of 14-90 days (70.1%, 95% CI: -145.4 to 96.4) was higher than that of the groups with a vaccination interval of 90-149 days (18.7%, 95% CI: -42.4% to 53.6%) and ≥150 days (21.2%, 95% CI: -18.8% to 47.7%).Conclusions: A moderate VE against influenza A(H1N1)pdm09 and a low VE against influenza A(H3N2) were observed in Beijing during the 2022-2023 influenza season, a season characterized with a delayed and high-intensity influenza epidemic. VE appears to be better within three months after vaccination. Our findings indicate a potential need for the optimization of vaccination policies and underscore the importance of continuous monitoring of influenza to enhance vaccines and optimizing vaccination timing.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511380/pdf/","citationCount":"0","resultStr":"{\"title\":\"Influenza Vaccine Effectiveness against Influenza A-Associated Outpatient and Emergency-Department-Attended Influenza-like Illness during the Delayed 2022-2023 Season in Beijing, China.\",\"authors\":\"Li Zhang, Guilan Lu, Chunna Ma, Jiaojiao Zhang, Jia Li, Wei Duan, Jiaxin Ma, Weixian Shi, Yingying Wang, Ying Sun, Daitao Zhang, Quanyi Wang, Da Huo\",\"doi\":\"10.3390/vaccines12101124\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: During the 2022-2023 influenza season, the influenza activities in most regions of China were postponed, including Beijing. The unusually delayed influenza epidemic posed a challenge to the effectiveness of the influenza vaccine.Methods: Using the test-negative design, we evaluated influenza vaccine effectiveness (VE) during the 2022-2023 influenza season against influenza A-associated outpatient and emergency-department-attended influenza-like illness (ILI) in Beijing, China, from 9 January to 30 April 2023.Results: The analysis included 8301 medically attended ILI patients, of which 1342 (46.2%) had influenza A(H1N1)pdm09, 1554 (53.4%) had influenza A(H3N2), and 11 (0.4%) had co-infection of the two viruses. VE against influenza A-associated ILI patients was 23.2% (95% CI: -6.5% to 44.6%) overall, and 23.1%, 9.9%, and 33.8% among children aged 6 months to 17 years, adults aged 18-59 years, and adults aged ≥60 years, respectively. VE against influenza A(H1N1)pdm09 and against influenza A(H3N2) were 36.2% (95% CI: -1.9% to 60.1%) and 9.5% (95% CI: -34.1% to 39.0%), respectively. VE of the group with vaccination intervals of 14-90 days (70.1%, 95% CI: -145.4 to 96.4) was higher than that of the groups with a vaccination interval of 90-149 days (18.7%, 95% CI: -42.4% to 53.6%) and ≥150 days (21.2%, 95% CI: -18.8% to 47.7%).Conclusions: A moderate VE against influenza A(H1N1)pdm09 and a low VE against influenza A(H3N2) were observed in Beijing during the 2022-2023 influenza season, a season characterized with a delayed and high-intensity influenza epidemic. VE appears to be better within three months after vaccination. Our findings indicate a potential need for the optimization of vaccination policies and underscore the importance of continuous monitoring of influenza to enhance vaccines and optimizing vaccination timing.\",\"PeriodicalId\":23634,\"journal\":{\"name\":\"Vaccines\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2024-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511380/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/vaccines12101124\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines12101124","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：在2022-2023年流感季节，包括北京在内的中国大部分地区的流感活动被推迟。异常延迟的流感疫情对流感疫苗的有效性提出了挑战：方法：我们采用阴性试验设计，评估了2022-2023年流感季节期间流感疫苗对中国北京2023年1月9日至4月30日期间甲型流感相关门诊和急诊流感样病例（ILI）的有效性（VE）：分析包括8301名就诊的ILI患者，其中1342人（46.2%）感染甲型H1N1流感pdm09，1554人（53.4%）感染甲型H3N2流感，11人（0.4%）同时感染两种病毒。甲型流感相关 ILI 患者的总体 VE 为 23.2%（95% CI：-6.5% 至 44.6%），6 个月至 17 岁儿童、18 至 59 岁成人和年龄≥60 岁成人的 VE 分别为 23.1%、9.9% 和 33.8%。甲型 H1N1 pdm09 流感和甲型 H3N2 流感的 VE 分别为 36.2%（95% CI：-1.9% 至 60.1%）和 9.5%（95% CI：-34.1% 至 39.0%）。接种间隔为 14-90 天的接种组的 VE 值（70.1%，95% CI：-145.4 至 96.4）高于接种间隔为 90-149 天（18.7%，95% CI：-42.4% 至 53.6%）和≥150 天（21.2%，95% CI：-18.8% 至 47.7%）的接种组：在2022-2023年流感流行季节，北京观察到甲型H1N1 pdm09流感的中度VE和甲型H3N2流感的低VE。接种后三个月内的VE似乎较好。我们的研究结果表明了优化疫苗接种政策的潜在需求，并强调了持续监测流感以加强疫苗和优化疫苗接种时机的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Influenza Vaccine Effectiveness against Influenza A-Associated Outpatient and Emergency-Department-Attended Influenza-like Illness during the Delayed 2022-2023 Season in Beijing, China.

Background: During the 2022-2023 influenza season, the influenza activities in most regions of China were postponed, including Beijing. The unusually delayed influenza epidemic posed a challenge to the effectiveness of the influenza vaccine.

Methods: Using the test-negative design, we evaluated influenza vaccine effectiveness (VE) during the 2022-2023 influenza season against influenza A-associated outpatient and emergency-department-attended influenza-like illness (ILI) in Beijing, China, from 9 January to 30 April 2023.

Results: The analysis included 8301 medically attended ILI patients, of which 1342 (46.2%) had influenza A(H1N1)pdm09, 1554 (53.4%) had influenza A(H3N2), and 11 (0.4%) had co-infection of the two viruses. VE against influenza A-associated ILI patients was 23.2% (95% CI: -6.5% to 44.6%) overall, and 23.1%, 9.9%, and 33.8% among children aged 6 months to 17 years, adults aged 18-59 years, and adults aged ≥60 years, respectively. VE against influenza A(H1N1)pdm09 and against influenza A(H3N2) were 36.2% (95% CI: -1.9% to 60.1%) and 9.5% (95% CI: -34.1% to 39.0%), respectively. VE of the group with vaccination intervals of 14-90 days (70.1%, 95% CI: -145.4 to 96.4) was higher than that of the groups with a vaccination interval of 90-149 days (18.7%, 95% CI: -42.4% to 53.6%) and ≥150 days (21.2%, 95% CI: -18.8% to 47.7%).

Conclusions: A moderate VE against influenza A(H1N1)pdm09 and a low VE against influenza A(H3N2) were observed in Beijing during the 2022-2023 influenza season, a season characterized with a delayed and high-intensity influenza epidemic. VE appears to be better within three months after vaccination. Our findings indicate a potential need for the optimization of vaccination policies and underscore the importance of continuous monitoring of influenza to enhance vaccines and optimizing vaccination timing.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

8.90

自引率

16.70%

发文量

1853

审稿时长

18.06 days

期刊介绍： Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.